Convert the discussion guide into a json with the following format U
Use the exact verbiage from the discussion guide

## Example Format
{
    "blocks": [
        {
            "title": "Mental moel of Type-2 (T2) inflammation in COPD",
            "questions": [
                {
                    "big_question": "When you say ‘T2 phenotype’ in COPD, what do you *specifically* mean in day-to-day practice?",
                    "probes": [
                        "How do you describe its pathophysiology to colleagues/trainees? Any overlap language with asthma/ACO clinics?",
                        "Which clinical signals move it from “possible” → “actionable”? (e.g., eos counts, exacerbation pattern, symptom clusters, response history).",
                        "Rural vs urban: does lab repeatability/turnaround alter your confidence?"
                    ]
                },
                {
                    "big_question": "Which **biomarkers and cutoffs** do you actually trust enough to act on?",
                    "probes": [
                        "Eosinophil thresholds you use (single vs repeated; stability over time; steroid confounding).",
                        "How exacerbation history, CAT, spirometry, and comorbidities weigh in.",
                        "What from GOLD 2025—if anything—changed your thresholding or sequencing?"
                    ]
                }
            ]
        },
        {
            "title": "From triple optimization → biologic add-on (inflection points)",
            "questions": [
                {
                    "big_question": "Walk me through your *last* patient who moved from optimized triple therapy to a biologic: what were the exact inflection points?",
                    "probes": [
                        "What does “optimized” triple mean in your clinic (device technique, adherence checks, rehab access, exacerbation prevention)?",
                        "What finally flipped you: frequent exacerbations, eos trends, lung-function trajectory, QoL plateau, steroid toxicity concerns?"
                    ]
                },
                {
                    "big_question": "How do you reconcile **pivotal dupilumab data** with clinic realities?",
                    "probes": [
                        "Which outcomes matter most to *you* (exacerbation reduction, FEV₁, QoL), and what’s your “clinically meaningful” bar?",
                        "Does academic vs community setting shift your bar? Does local access to ILD/asthma overlap clinics or rehab change decisions?",
                        "What would a head-to-head vs optimized triple need to show to move earlier?"
                    ]
                }
            ]
        },
        {
            "title": "Access choreography & care pathways",
            "questions": [
                {
                    "big_question": "What *evidence pack* do you assemble for prior auth, and how does it vary by payer (Medicare Part D vs commercial)?",
                    "probes": [
                        "Typical documentation: eos history (values/dates), exacerbations, prior therapies & duration, adherence checks, rehab and smoking-cessation documentation, comorbidity notes.",
                        "Where do P&T criteria diverge from your clinical threshold? Any patterns by plan or region?"
                    ]
                },
                {
                    "big_question": "How do **list-price optics and OOP** realities land in conversations with patients?",
                    "probes": [
                        "How you set expectations around specialty-pharmacy onboarding, shipment cadence, injection training, monitoring.",
                        "Urban vs rural: transportation constraints, lab availability; who does the injection training (office vs SP nurse); sample programs/bridge pathways.",
                        "What makes you *abandon* the add-on plan (denials, unaffordable copay, delays)?"
                    ]
                }
            ]
        },
        {
            "title": "Positioning language with patients & care team",
            "questions": [
                {
                    "big_question": "Exactly *how* do you position a biologic alongside—or instead of—further inhaler intensification?",
                    "probes": [
                        "Sample phrases you use for mechanism (IL-4/IL-13 pathway), expected benefits, time-to-benefit, and who is/isn’t a candidate.",
                        "Differences in language for steroid-sensitive, polypharmacy, or rehab-limited patients."
                    ]
                },
                {
                    "big_question": "What does **success** look like at 3 / 6 / 12 months, and how do you track it?",
                    "probes": [
                        "Exacerbations (moderate/severe), rescue SABA use, CAT/SGRQ, work/activity days, steroid bursts, ED visits, PROs.",
                        "What *specific* changes trigger discontinuation vs continuation? Who owns follow-up (pulm vs PCP vs allergy) and how is data shared?"
                    ]
                }
            ]
        },
        {
            "title": "Uncertainties, evidence requests, and future behavior",
            "questions": [
                {
                    "big_question": "Where are you *still* uncertain—and what new evidence would change your behavior?",
                    "probes": [
                        "Subgroup data by eos ranges, durability, safety in older multimorbid populations, steroid-sparing, mortality, rehab interplay.",
                        "Comparative effectiveness vs further inhaler tweaks; pragmatic RWE in community settings; rural access solutions."
                    ]
                },
                {
                    "big_question": "If GOLD 2025/26 were to add one clarification to make your life easier, what would it be?",
                    "probes": [
                        "Biomarker cadence/confirmatory rules; clear eos cutoffs; sequencing guidance with triple therapy; monitoring algorithms."
                    ]
                }
            ]
        }
    ],
}

## Discussion Guide
{{discussion_guide}}
